Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 3/20 | 0.54 |
| ▸ | CA9 | Q16790 | 3/20 | 0.54 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.54 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.54 |
| ▸ | ATM | Q13315 | 1/20 | 0.54 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.54 |
| ▸ | CA1 | P00915 | 3/20 | 0.49 |
| ▸ | CA2 | P00918 | 3/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | CA4 | P22748 | 1/20 | 0.47 |
| ▸ | DRD4 | P21917 | 2/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.45 |
| ▸ | MEN1 | O00255 | 2/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.44 |
| ▸ | DRD2 | P14416 | 1/20 | 0.44 |
| ▸ | DRD3 | P35462 | 1/20 | 0.44 |
| ▸ | SCN8A | Q9UQD0 | 1/20 | 0.43 |
| ▸ | BCHE | P06276 | 1/20 | 0.43 |
| ▸ | ACHE | P22303 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9550978 | 0.85 | ALDH1A1 (0.50) | CA12CA9CYP3A4CA1CA2 | |
| SCHEMBL241683 | 0.80 | CA9 (0.54) | CA12CA9CYP1A2CYP3A4ATM | |
| SCHEMBL14219017 | 0.80 | ALDH1A1 (0.47) | CA12CA9CYP3A4CA1CA2 | |
| SCHEMBL9703293 | 0.80 | DRD2 (0.59) | CYP1A2CYP3A4KMT2AALDH1A1DRD4 | |
| SCHEMBL31606584 | 0.79 | CA12 (0.49) | CA12CA9CYP1A2CYP3A4ATM | |
| SCHEMBL7809908 | 0.79 | DRD4 (0.54) | CA12CA9CA1CA2KMT2A | |
| SCHEMBL9169477 | 0.78 | ALDH1A1 (0.44) | CA12CA9CYP3A4CA1CA2 | |
| SCHEMBL29803178 | 0.78 | CA12 (0.58) | CA12CA9CYP1A2CYP3A4ATM | |
| SCHEMBL28629399 | 0.78 | ALDH1A1 (0.44) | CA12CA9CYP1A2L3MBTL1CA1 | |
| SCHEMBL7028389 | 0.78 | CNR2 (0.50) | CA12CA9CYP1A2CYP3A4ATM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190300492-A1 | METHODS FOR PRODUCING VILOXAZINE SALTS AND NOVEL POLYMORPHS THEREOF | SUPERNUS PHARMACEUTICALS, INC. (US) | 2019-10-03 | — | — | US | claimed |
| US-20190300492-A1 | METHODS FOR PRODUCING VILOXAZINE SALTS AND NOVEL POLYMORPHS THEREOF | SUPERNUS PHARMACEUTICALS, INC. (US) | 2019-10-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190300492-A1 | METHODS FOR PRODUCING VILOXAZINE SALTS AND NOVEL POLYMORPHS THEREOF | CYP3A5, VIL1, CYP3A4 | CA12 1435/4885CA9 3061/4885CYP1A2 12/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.